Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Starts China Trial of Novel mAb as Extended-Dose Psoriasis Therapy

publication date: Feb 17, 2023

Suzhou Innovent Bio has dosed the first patient in a China Phase III trial of picankibart, a novel mAb, as an extended-dose therapy for psoriasis. Picankibart (IBI112) specifically binds to IL-23p19 subunit, preventing IL-23 from binding to cell surface receptors and inhibiting the IL-23 receptor-mediated signaling pathway. Participants in the trial will be treated with an injected dose of picankibart every 12 weeks over a 68-week schedule. The candidate was developed in-house by Innovent, known mainly for its oncology portfolio, though the company is also active in metabolic, autoimmune, ophthalmology and other diseases. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital